Rivaroxaban 20 MG

DRUG6 trials

Conditions

Anticoagulant Adverse ReactionAnticoagulants; IncreasedAtrial FibrillationBleedingHeavy Menstrual BleedingLeft Ventricular ThrombosisNeoplasmsNonvalvular Atrial Fibrillation

Phase 1

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

CompletedNCT03083704

Portola PharmaceuticalsBleeding

Start: 2017-02-26End: 2017-09-28Updated: 2023-08-08

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

CompletedNCT03282643

Capital Medical UniversityNeoplasms

Start: 2016-02-16End: 2019-04-01Updated: 2019-04-16

Phase 3

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi

CompletedNCT03926780

The Young Investigator Group of Cardiovascular ResearchAnticoagulants; Increased, Left Ventricular Thrombosis

Start: 2018-12-01End: 2020-05-01Updated: 2020-06-11

Phase 4

AntiCoagulants and COGnition

NCT04073316

University Hospital, AngersNonvalvular Atrial Fibrillation

Start: 2020-02-13End: 2023-02-28Target: 48Updated: 2022-07-27

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

RecruitingNCT06187311

Korea University Anam HospitalAnticoagulant Adverse Reaction, Atrial Fibrillation

Start: 2023-01-12End: 2027-06-30Target: 940Updated: 2024-01-05

Unknown Phase

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

CompletedNCT04477837

Cardioangiologisches Centrum BethanienHeavy Menstrual Bleeding

Start: 2020-10-15End: 2024-06-15Updated: 2024-08-21

Related Papers

Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.

2019-05-018 citations